Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by kingposton Nov 27, 2016 1:30pm
144 Views
Post# 25518869

thoughts on Lilly's results......

thoughts on Lilly's results......I like  the PMN tech , and am very hopeful it succeeds; but I am thinking Lilly would be smart enough to pick soluable AB prion types that have a high correlation with AD and as such their recent failure in their high powered study, to me is a negative for PMN ---- just picking numbers out of the air partly  but on the AB side maybe 50% of the potential with PMN may be lost ....  however the 5 prions  targeted by pmn may be totally different than what Lilly targeted so PMN still has a chance... but just considering the power and money spent by Lilly might lead you to think they would have picked the target soluable prion(s) carefully...I think PMN will address the Lilly results more after Lilly come out with more detail in early 2017....
On the Tau Tangle side...which they are not yet recearching in the current 100 patient study, I think the potential is unchanged, and their science looks stromg to me, ....but I am not sure when they will do a similar study on Tau....

Bullboard Posts